New data reveals a surge in demand for obesity, diabetes, and mental health medications in Canada
Projected 7.4% rise in Canada’s medical costs shifts focus to chronic conditions and efficiency
Pipeline Monitor reveals growth in clinical trials, highlighting impactful treatments on the horizon
Apotex's growth continues with a 2023 acquisition and possible IPO plans underway
CHPI report finds Canadian supply could deplete quickly under US demand for lower drug costs
Oncolytics and others advance cancer therapies as the FDA approves 16 new oncology treatments in 2024
